RT @NatRevRheumatol: #ResearchHighlight | Sustained remission in PsA with secukinumab #psoriaticarthritis #IL6 #therapy Read the original r…
RT @NatRevRheumatol: #ResearchHighlight | Sustained remission in PsA with secukinumab #psoriaticarthritis #IL6 #therapy Read the original r…
RT @NatRevRheumatol: #ResearchHighlight | Sustained remission in PsA with secukinumab #psoriaticarthritis #IL6 #therapy Read the original r…
RT @NatRevRheumatol: #ResearchHighlight | Sustained remission in PsA with secukinumab #psoriaticarthritis #IL6 #therapy Read the original r…
RT @NatRevRheumatol: #ResearchHighlight | Sustained remission in PsA with secukinumab #psoriaticarthritis #IL6 #therapy Read the original r…
#ResearchHighlight | Sustained remission in PsA with secukinumab #psoriaticarthritis #IL6 #therapy Read the original research from @ArthritisRes here https://t.co/h5TjEONh5m Read our #InBrief here https://t.co/qOx3jfIFb9
FUTURE 2 study: #Secukinumab provides sustained PASDAS-defined remission in #psoriatic arthritis and improves health-related quality of life in patients achieving remission https://t.co/aEYPssH2vh #rheumedu